title: Intravitreal triamcinolone acetonide for the treatment of immune recovery uveitis macular edema.
abstract: OBJECTIVE
  To evaluate the use of intravitreal triamcinolone (IVTA) for the treatment of macular edema secondary to immune recovery uveitis (IRU) in patients with AIDS.
  
  
  METHODS
  Prospective, consecutive, interventional case series.
  
  
  METHODS
  Eight eyes of 7 patients receiving 13 injections.
  
  
  METHODS
  Prospective, consecutive, interventional case series of 13 injections involving 8 eyes in 7 patients who underwent an intravitreal injection of 20 mg decanted triamcinolone acetate for fluorescein angiographically proven IRU-related macular edema.
  
  
  METHODS
  The primary outcome measure was vision (using the Early Treatment Diabetic Retinopathy Study chart). Other outcome measures included fluorescein angiography and optical coherence tomography.
  
  
  RESULTS
  Visual acuity improved at all time points and was statistically significant at the 1-month and 3-month follow-up examinations. The average visual improvement was 3 lines at 3 months. Retinal volume and thickness improvement were statistically significant at all time points. All patients had a minimum follow-up of 9 months, and there were no cases of cytomegalovirus reactivation.
  
  
  CONCLUSIONS
  Previous studies showed that treatment with sub-Tenon repository steroids for the treatment of macular edema of IRU was only marginally effective. However, the current study shows that IVTA can be an effective short-term treatment for macular edema secondary to IRU in patients with AIDS. Longer follow-up is needed to assess the durability of the effect and to monitor for longer-term complications and outcomes.
authors.affiliation: Jacobs Retina Center, Department of Ophthalmology, University of California, San Diego, La Jolla, California 92093, USA.
authors.forename: Victoria L
authors.initials: VL
authors.lastname: Morrison
authors.forename: Igor
authors.initials: I
authors.lastname: Kozak
authors.forename: Laurie D
authors.initials: LD
authors.lastname: LaBree
authors.forename: Stanley P
authors.initials: SP
authors.lastname: Azen
authors.forename: Ozcan O
authors.initials: OO
authors.lastname: Kayicioglu
authors.forename: William R
authors.initials: WR
authors.lastname: Freeman
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000276:immunology; D000328:Adult; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D017726:Cytomegalovirus Retinitis / Q000188:drug therapy / Q000276:immunology; D005260:Female; D005451:Fluorescein Angiography; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007267:Injections; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D041623:Tomography, Optical Coherence; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*; D014605:Uveitis / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D005938:Glucocorticoids; D014222:Triamcinolone Acetonide